Eiko LifeSciences share price, P/E, ROE & financials

As of 6 Nov 2026, Eiko LifeSciences trades at 15.5× trailing earnings, below the industry P/E of 22.1×, and the shares are 14% below their 52-week high. Its ROCE of 10% is the second-lowest among the 7 largest Specialty Chemicals peers, and sales and net profit grew 36% and 80% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹75 Cr, ranked 155th of 204 Specialty Chemicals companies by market cap; the shares fell 17% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹52.00
Day high: ₹52.49
Day low: ₹50.00
Prev. close: ₹51.44
Volume: 5.4K

Health check

2 good · 1 fair · 3 to check

ReturnsBehind
−17.1% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 15.5 vs industry 22.1.
GrowthStrong
Sales +36.2%, profit +80.1% a year over 3 years.
ProfitabilityWeak
ROCE 10.1% vs peer median 24.4%.
Balance sheetFair
Debt 0.07× equity, interest covered 22.6×, Piotroski 4 of 9.
Red flags1 to check
Return on equity is low at 7.2%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Specialty Chemicals

203 listed peers. Screen the industry

Small cap

₹75 Cr, #155 of 204 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹59 Cr · profit ₹5 Cr

Market cap: ₹75 Cr; Small cap
P/E: 15.5; Industry 22.1
Price to book: 1.06; Peers 13.33
Dividend yield: 0.00%
ROE: 7.2%; Peers 23.0%
ROCE: 10.1%; Peers 24.4%
Debt to equity: 0.07; Debt ₹4.73 Cr
EPS (TTM): ₹3.28
OPM (TTM): 13.4%; Net margin 8.3%
Sales growth: +56.4%; Latest quarter vs a year ago
Profit growth: +43.1%; Latest quarter vs a year ago
Price to sales: 1.28; EV/EBITDA 8.2

Strengths

Practically debt-free.
Quarterly profit up 43.1% on a year ago.
Quarterly sales up 56.4% on a year ago.
P/E of 15.5 against an industry P/E of 22.1.

Risks to check

Return on equity is low at 7.2%.

Derived automatically from reported figures. Not a recommendation.

About Eiko LifeSciences

Eiko LifeSciences Limited, together with its subsidiary, manufactures and supplies specialty chemicals, fine chemicals, and active pharmaceutical ingredients in India and internationally. It offers speciality chemicals and intermediates, such as lasamide, trichloro salicylic acid, chloroacetyl xylidide, and thiodipropionic acid; agrochemical intermediates; and cosmetic emollients, including isopropyl oleate, isopropyl palmitate, methyl myristate, butyl…

Headquarters: Thane
Employees: 7
Sector: Basic Materials
ISIN: INE666Q01016
Website: eikolifesciences.com

Price range

52 weeks

₹43.00₹59.00

Today

₹50.00₹52.49

Avg volume (3M): 12.6K
1-year return: minus 17.1%
From 52-week high: minus 14.1%

Peers · Specialty Chemicals

Capital-heavy industry columns

Compare with peers Screen the whole industry

Company
ASIANPAINTAsian Paints	2,546.00	plus 0.88%	2,44,025	50.5	35.0	24.4%	18.9%	0.21	1.1%	plus 1.5%
SOLARINDSSolar Industries India	18,608.00	plus 0.48%	1,68,384	74.4	64.1	29.5%	27.8%	0.22	12.4%	plus 35.9%
PIDILITINDPidilite Industries	1,579.00	plus 1.63%	1,60,827	60.0	44.4	28.5%	23.5%	0.03	7.4%	plus 6.8%
LINDEINDIALinde India	6,859.00	plus 8.73%	58,496	118.4	64.2	16.3%	31.5%	0.23	–	plus 5.4%
BERGEPAINTBerger Paints India	478.35	minus 5.28%	55,776	45.4	29.4	20.6%	15.3%	0.15	4.2%	minus 6.0%
FLUOROCHEMGujarat Fluorochemicals	4,665.50	minus 0.94%	51,251	75.9	44.0	9.6%	24.1%	0.26	−4.5%	plus 28.0%
ACUTAASAcutaas Chemicals	3,786.60	plus 0.42%	31,001	70.9	64.1	27.7%	39.4%	0.01	29.4%	plus 105.6%
EIKOEiko LifeSciences	50.69	minus 1.46%	75	15.5	18.6	10.1%	13.4%	0.07	36.2%	minus 17.1%
Median of 7 peers	–	0.48%	58,496	70.9	44.4	24.4%	24.1%	0.21	5.8%	6.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
10.7	11.7	12	18.3	16.7
9.2	9.9	10.1	16.1	14.8
1.5	1.8	1.9	2.3	1.9
14.1%	15.1%	15.7%	12.5%	11.6%
0.3	0.3	0.3	0.1	0.4
0	0.1	0.1	0.1	0.1
0.3	0.3	0.3	0.3	0.3
1.5	1.7	1.9	2	2
24.8%	24.9%	25.1%	25.8%	24.6%
0.9	1.1	1.2	1.3	1.3
0.66	0.78	0.88	0.86	0.76

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +36.2%
Profit CAGR 3Y: +80.1%
EPS CAGR 3Y: +59.2%
ROE: 7.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
18.3	27.9	36	46.3
–	+52.4%	+29.0%	+28.4%
17.4	26.7	34.2	42.7
1	1.3	1.8	3.5
5.2%	4.5%	5.1%	7.7%
0.8	0.2	1.8	4.9
0.2	0.1	0.2	0.3
0.6	0.3	0.7	1
0	–	0.4	0
1	1	3.1	7.1
25.1%	23.6%	24.3%	25.2%
0.8	0.8	2.1	4.5
–	minus 2.3%	+180.2%	+113.5%
0.79	0.73	1.62	3.19

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
8.3	12.9	13.8	14.3
21.1	37.8	43	54.4
0.1	–	2.8	4.7
1.6	2.1	6.5	15.9
31	52.7	66.1	89.4
13.9	13.6	23.1	22.1
1.2	4	0	8.1
0.6	13.3	11.8	13.6
15.4	21.8	31.2	45.6
31	52.7	66.1	89.4

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4.2	−7.5	2.8	2.3
0.9	−3.1	−11.3	−8.6
−4.7	0.4	7	8.2
0.4	−10.2	−1.6	1.8
−0.2	−0.3	−10.3	–
4	−7.5	−7.5	2.3

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you